TY  - BOOK
PY  - 2018
UR  - http://hdl.handle.net/10668/4231
T2  - Informe de evaluación de medicamentos
AB  - En este informe de la European Network for Health Technology Assessment (EUnetHTA), se evalúa la eficacia y seguridad de regorafenib en el tratamiento de pacientes adultos con carcinoma hepatocelular que han sido tratados previamente con sorafenib....
LA  - spa
PB  - Agencia de Evaluación de Tecnologías Sanitarias de Andalucía, Consejería de Salud, Junta de Andalucía
KW  - Carcinoma hepatocelular
KW  - Tratamiento farmacológico
KW  - Quimioterapia
KW  - Evaluación de medicamentos
KW  - Terapéutica
KW  - Adultos
KW  - Regorafenib
KW  - Sorafenib
KW  - Carcinoma, hepatocellular
KW  - Therapeutics
KW  - Drug therapy
KW  - Drug evaluation
KW  - Adult
KW  - Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms::Carcinoma, Hepatocellular
KW  - Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy
KW  - Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Evaluation Studies as Topic::Drug Evaluation
KW  - Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics
KW  - Medical Subject Headings::Persons::Persons::Age Groups::Adult
TI  - Regorafenib en monoterapia en pacientes con carcinoma hepatocelular previamente tratados con sorafenib
T2  - Regorafenib indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma who have been previously treated with sorafenib
TY  - book
ER  -